A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection
A Phase I, Multicentre, Open-label Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII, Fc Fusion Protein for Injection in Children With Severe Hemophilia A
Sponsor: Jiangsu Gensciences lnc.
A PHASE1 clinical study on Hemophilia A, this trial is completed. The trial is conducted by Jiangsu Gensciences lnc. and has accumulated 7 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jul 2022 — Jun 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Apr 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Jun 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu Gensciences lnc.
For direct contact, visit the study record on ClinicalTrials.gov .